Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
- PMID: 20796301
- PMCID: PMC2949590
- DOI: 10.1186/alzrt48
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Abstract
Introduction: The present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would be: 1) practical, easy and quick to administer for an experienced clinician; 2) validated for AD; 3) multi-domain: covering the AD-relevant areas of cognition, activities of daily living, behavior, communication/social interaction, and quality of life; 4) applicable to all AD severity stages; 5) able to monitor disease progression; and 6) sensitive to measure therapy effects.
Methods: The National Library of Medicines' MEDLINE database was searched for the years 1981 to September 2008, using a set of keywords aiming to select instruments which cover at least some of the requirements for an ideal practical AD scale for therapy evaluation. Measures for AD staging and screening tests were not considered for review.
Results: Of 1,902 articles resulting from the literature search, 68 relevant AD scales were identified. Most of them were scales that predominantly measure the severity of major dysfunctions in particular AD domains. Only five scales met some of the requirements for a practical multi-domain AD scale, but did not possess all required characteristics.
Conclusions: Despite the multitude of AD scales for various purposes, there remains a need for a new multi-domain and easy to administer AD scale for assessment of disease progression and response to therapy in daily medical practice.
Similar articles
-
How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?Neurodegener Dis. 2014;13(2-3):197-9. doi: 10.1159/000353748. Epub 2013 Aug 7. Neurodegener Dis. 2014. PMID: 23942173 Review.
-
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1. Alzheimers Res Ther. 2016. PMID: 26883213 Free PMC article.
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].Encephale. 2003 May-Jun;29(3 Pt 1):266-72. Encephale. 2003. PMID: 12876552 French.
-
Souvenaid for Alzheimer's disease.Cochrane Database Syst Rev. 2020 Dec 15;12(12):CD011679. doi: 10.1002/14651858.CD011679.pub2. Cochrane Database Syst Rev. 2020. PMID: 33320335 Free PMC article.
Cited by
-
Validation of the Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment (ETAM).BMC Geriatr. 2016 May 26;16:111. doi: 10.1186/s12877-016-0271-9. BMC Geriatr. 2016. PMID: 27229937 Free PMC article. Clinical Trial.
-
Development of a novel convenient Alzheimer's disease assessment scale, the ABC Dementia Scale, using item response theory.Geriatr Gerontol Int. 2019 Jan;19(1):18-23. doi: 10.1111/ggi.13552. Epub 2018 Nov 22. Geriatr Gerontol Int. 2019. PMID: 30467944 Free PMC article.
-
Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease.Alzheimers Dement (N Y). 2019 May 20;5:164-174. doi: 10.1016/j.trci.2019.04.001. eCollection 2019. Alzheimers Dement (N Y). 2019. PMID: 31193334 Free PMC article.
-
Development of a Rasch-Built Amyotrophic Lateral Sclerosis Impairment Multidomain Scale to Measure Disease Progression in ALS.Neurology. 2023 Aug 8;101(6):e602-e612. doi: 10.1212/WNL.0000000000207483. Epub 2023 Jun 13. Neurology. 2023. PMID: 37311649 Free PMC article.
-
Describing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study.J Alzheimers Dis. 2016;52(3):1065-80. doi: 10.3233/JAD-150852. J Alzheimers Dis. 2016. PMID: 27079700 Free PMC article.
References
-
- Khachaturian ZS, Radebaugh TS, (Eds) Alzheimer's Disease: Cause(s), Diagnosis, Treatment, and Care. Boca Raton, FL: CRC Press; 1996.
-
- Lawton MP. In: The Concept and Measurement of Quality of Life in the Frail Elderly. Barren JE, Lubben JE, Rowe JC, Deutschman DE, editor. New York: Academic Press; 1991. A multidimensional view of quality of life; pp. 3–27.
-
- Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias (CPMP/EWP/553/95 Rev.1) http://www.emea.europa.eu
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous